WELIREG®
[Indication Placeholder]
WELIREG is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies.
- WELIREG can cause severe anemia that can require blood transfusion. Monitor for anemia before initiation of, and periodically throughout, treatment.
- WELIREG can cause severe hypoxia that may require discontinuation or supplemental oxygen. Monitor oxygen saturation before initiation of, and periodically throughout, treatment.
- WELIREG can cause embryo-fetal harm. Verify pregnancy status of females of reproductive potential prior to the initiation of WELIREG. Advise patients of these risks and the need for highly effective contraception. Coadministration of WELIREG with hormonal contraceptives may lead to contraceptive failure.
[SSI Placeholder]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.